WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) today announced the publication of data demonstrating that SYMBICORT Inhalation Aerosol 320/9 µg twice daily had a safety profile similar to ...
DENVER--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) today announced results from a long-term study comparing SYMBICORT ® (budesonide/ formoterol fumarate dihydrate) Inhalation Aerosol 160/4.5 mcg with ...
Wilmington, DE – May 22, 2007 – New data demonstrated that the combination asthma therapy, SYMBICORT® (budesonide/formoterol fumarate dihydrate), led to ...
August 22, 2008 — A budesonide/formoterol (Symbicort, AstraZeneca) pressurized metered-dose inhaler (pMDI) showed safety and better asthma control versus budesonide alone, according to the results of ...
(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) SYMBICORT is a combination asthma medication that contains both an inhaled corticosteroid (ICS ...
The pediatric approval was based on the results of the Phase 3 CHASE (ChildHood Asthma Safety and Efficacy) 3 trial. The Food and Drug Administration (FDA) has approved Symbicort (budesonide and ...
The sNDA submission is based on results from two pivotal efficacy and safety trials, SHINE and SUN, with SYMBICORT pressurized metered dose inhaler (pMDI). (2), (3) Of note, both trials showed a ...
AstraZeneca Announces Symbicort Is Now Available In The U.S. U.S. Asthma Sufferers Now Have a New Choice of Combination Therapy to Help Achieve Asthma Control LONDON ...
Howard Hutchinson, M.D., Chief Medical Officer of AstraZeneca, said, "The safety and efficacy of SYMBICORT have been demonstrated in numerous clinical trials and from extensive post-marketing use ...
The studies examined the efficacy of Symbicort pressurized metered dose inhaler (pMDI) 160/4.5mcg vs. formoterol 4.5mcg in reducing COPD exacerbations in adults with moderate to severe COPD. The FDA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results